Amgen Said to Boost Bid for Onyx to $130 a Share

Amgen Said to Boost Bid for Onyx to $130 a Share Play

Aug. 6 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Olivia Sterns reports on Bloomberg Television's "Street Smart." (Source: Bloomberg)

  • On Air Now

    PAID PROGRAMMING Watch Now

  • Next

    Charlie Rose

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus